## I. AMENDMENTS

Please cancel claims 38, 53 and 57; add new claims 60 to 63; and amend the claims as indicated below. Upon entry of the present amendment, the status of the claims will be as follows:

1 to 30. (Cancelled)

31. (Currently Amended) A kit comprising:

(a) ~~an array of~~ a microarray comprising a plurality of uncharacterized antibodies located at discrete locations on a solid surface; and

(b) instructions for using the ~~array~~ microarray.

32. (Original) A kit according to claim 31 wherein the instructions are for identifying antibodies to a specific antigen, comparing protein expression in two or more populations of cells, characterizing a cell based on the pattern of protein expression produced thereby, or determining the effect of varying binding conditions on the binding affinity of the antibodies.

33. (Original) A kit according to claim 31 wherein the antibodies are monoclonal antibodies, polyclonal antibodies or antibody fragments.

34. (Original) A kit according to claim 33 wherein the antibody fragments are single chain antibodies.

35. (Original) A kit according to claim 31 wherein the antibodies are recombinant antibodies.

36. (Original) A kit according to claim 31 further comprising reagents for detecting an antigen and instructions for use thereof.

37. (Currently amended) ~~A kit comprising:~~

~~(a) an array of~~ A microarray comprising a plurality of uncharacterized antibodies located at discrete locations on a solid surface~~; and~~

~~(b) instructions for using the array; wherein the instructions are for diagnosing a disorder, characterizing a cell based on the pattern of protein expression produced thereby, or comparing protein expression in two or more populations of cells~~.

38. (Cancelled).

39. (Currently amended) ~~A kit~~ The microarray according to claim 37 wherein the antibodies are recombinant antibodies.

40. (Currently amended) ~~A kit~~ The microarray according to claim 37 wherein the antibodies are single chain antibodies.

41 to 50. (Cancelled)

51. (Previously Presented) The kit according to claim 31 wherein the source of the antibodies at each discrete location is known.

52. (Currently amended) The kit according to claim 31 ~~wherein the array is a~~ , said microarray having the locations of the antibodies arranged in an ordered matrix that is spatially addressable.

53. (Cancelled).

54. (Previously Presented) The kit according to claim 31 wherein the space between the discrete locations is treated to minimize non-specific binding to the solid support.

55. (Currently amended) ~~A kit~~ The microarray according to claim 37 wherein the source of the antibodies at each discrete location is known.

56. (Currently amended) ~~A kit~~ The microarray according to claim 37, said ~~wherein the array is a~~ microarray having the locations of the antibodies arranged in an ordered matrix that is spatially addressable.

57. (Cancelled).

58. (Currently amended) ~~A kit~~ The microarray according to claim 37 wherein the space between the discrete locations is treated to minimize non-specific binding to the solid support.

59. (Currently amended) ~~A kit~~ The microarray according to claim 37 wherein the antibodies are monoclonal antibodies, polyclonal antibodies or antibody fragments.

60. (New) The kit according to claim 31, wherein between 0.01 nanoliters and 100 nanoliters of the antibodies is spotted at each discrete location on the solid surface.

61. (New) The kit according to claim 31, wherein the microarray comprises 600 discrete locations per square centimeter.

62. (New) The kit according to claim 51, wherein the source of the antibodies is a known hybridoma cell line.

63. (New) The microarray according to claim 37, wherein between 0.01 nanoliters and 100 nanoliters of the antibodies is spotted at each discrete location on the solid surface.

64. (New) The microarray according to claim 37, which comprises 600 discrete locations per square centimeter.

65. (New) The microarray according to claim 55, wherein the source of the antibodies is a known hybridoma cell line.